dc.creator | Cordero Matia, María Elisa | es |
dc.creator | Bulnes Ramos, Ángel | es |
dc.creator | Aguilar Guisado, Manuela | es |
dc.creator | González Escribano, María Francisca | es |
dc.creator | Olivas, Israel | es |
dc.creator | Torre-Cisneros, Julian | es |
dc.creator | Gavaldá, Joan | es |
dc.creator | Pérez Romero, Pilar | es |
dc.date.accessioned | 2023-05-17T07:24:43Z | |
dc.date.available | 2023-05-17T07:24:43Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Cordero Matia, M.E., Bulnes Ramos, Á., Aguilar Guisado, M., González Escribano, M.F., Olivas, I., Torre-Cisneros, J.,...,Pérez Romero, P. (2020). Effect of influenza vaccination inducing antibody mediated rejection in solid organ transplant recipients. Frontiers in Immunology, 11, 1-10. https://doi.org/10.3389/fimmu.2020.01917. | |
dc.identifier.issn | 1664-3224 | es |
dc.identifier.uri | https://hdl.handle.net/11441/146159 | |
dc.description.abstract | Introduction: Our goal was to study whether influenza vaccination induced antibody mediated rejection in a large cohort of solid organ transplant recipients (SOTR).
Methods: Serum anti-Human Leukocyte Antigen (HLA) antibodies were determined using class I and class II antibody-coated latex beads (FlowPRATM Screening Test) by flow cytometry. Anti-HLA antibody specificity was determined using the single-antigen bead flow cytometry (SAFC) assay and assignation of donor specific antibodies (DSA)
was performed by virtual-crossmatch.
Results: We studied a cohort of 490 SOTR that received an influenza vaccination from 2009 to 2013: 110 (22.4%) received the pandemic adjuvanted vaccine, 59 (12%) within the first 6 months post-transplantation, 185 (37.7%) more than 6 months after transplantation and 136 (27.7%) received two vaccination doses. Overall, no differences of anti-HLA antibodies were found after immunization in patients that received the adjuvanted vaccine, within the first 6 months post-transplantation, or based on the type of organ transplanted. However, the second immunization dose increased the
percentage of patients positive for anti-HLA class I significantly compared with patients with one dose (14.6% vs. 3.8%; P = 0.003). Patients with pre-existing antibodies before vaccination (15.7% for anti-HLA class I and 15.9% for class II) did not increase reactivity after immunization. A group of 75 (14.4%) patients developed de novo anti HLA antibodies, however, only 5 (1.02%) of them were DSA, and none experienced allograft rejection. Only two (0.4%) patients were diagnosed with graft rejection with favorable outcomes and neither of them developed DSA.
Conclusion: Our results suggest that influenza vaccination is not associated with graft rejection in this cohort of SOTR. | es |
dc.description.sponsorship | Junta de Andalucía, Consejería de Salud PI-0119-2012 | es |
dc.description.sponsorship | Ministerio de Economía y Competitividad, Instituto de Salud Carlos III GR09/0041 | es |
dc.description.sponsorship | Ministerio de Economía y Competitividad, Instituto de Salud Carlos III PI14-00165 | es |
dc.description.sponsorship | Ministerio de Economía y Competitividad, Instituto de Salud Carlos III MPY110/18 | es |
dc.description.sponsorship | European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases REIPI RD12/0015/0001 | es |
dc.format | application/pdf | es |
dc.format.extent | 10 | es |
dc.language.iso | eng | es |
dc.publisher | Frontiers Media S.A. | es |
dc.relation.ispartof | Frontiers in Immunology, 11, 1-10. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Cytomegalovirus | es |
dc.subject | Alloreactivity | es |
dc.subject | Donor specific antibodies | es |
dc.subject | Anti-human leukocyte antigen | es |
dc.subject | Organ rejection | es |
dc.title | Effect of influenza vaccination inducing antibody mediated rejection in solid organ transplant recipients | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.identifier.doi | 10.3389/fimmu.2020.01917 | es |
dc.contributor.group | Universidad de Sevilla. CTS-203 Estudio de las Enfermedades Infecciosas | es |
dc.journaltitle | Frontiers in Immunology | es |
dc.publication.volumen | 11 | es |
dc.publication.initialPage | 1 | es |
dc.publication.endPage | 10 | es |